4th Biosimilars Congregation 2014

4th Biosimilars Congregation 2014

26-27 Feb 2014 at Thistle™ Marble Arch hotel, London, GB

Pharmaceuticals/Drug Discovery, Medical & Health Care

Submit new post
Thank you for posting.
Share it:

Speakers ({{speakersCount}})

Show all

4th Biosimilars Congregation 2014

“Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars”

26th& 27th February 2014, Thistle Marble Arch Hotel, London,UK
Contact: - Nisha: - +44 2079983304. Email – nisha@virtueinsight.com

• ChetakBuaria, Director - Alliance Management (Biosimilars), Merck Serono
• Mohamed Oubihi, Associate Director JAPAC, EU and Emerging Market Regulatory Affairs, Abbott
• Malcolm I Mitchell, Director, BioPharmaceuticals, Eli Lilly
• Cecil Nick, Vice President, Parexel
• Jean-Yves le Cotonnec, CEO, Triskel Integrated Services
• Bruno Flamion, Advisory Board Member, NDA Regulatory
• Martin Bluggel, CEO, Protagen Protein Services
• Kristie C. Kuhl, Executive Vice President, Makovsky (New York)
• Steinar Madsen, Medical Director, Department of Drug Information, Norwegian Medicines Agency
• Catherine Akers, Regulatory Affairs Manager - EU Policy, Amgen
• Tony Williams, CEO, TWC Pharma Consulting
• Duncan Emerton, Senior Director, Syndicated Insights & Analysis, FirstWord
• François Lawny, Director of Biotechnology, Triskel Integrated Services
• Sandy Eisen, Chief Medical Officer, Frontline Pharma Consulting (Former CMO, Teva Pharmaceuticals)
• Lincoln Tsang, Partner, Arnold & Porter
• Peter Wittner, Senior Consultant, Interpharm Consultancy (Former Managing Director Ranbaxy UK)
• Brij Patel, CEO, RegExcelconsulting(Former Biological Assessor, MHRA)
• Maria Isabel Manley, Partner & Head of the Regulatory Practice, Bristows
Plus Many More...

Bronze Sponsor : - SGS
Bronze Sponsor : - Protagen
Associate Sponsor : - TWC
Associate Sponsor : - Bytemindz

• How should the pharma and generics industries approach the rapidly emerging and developing biosimilar market? The future of next generation Biosimilars
• Getting to the market faster with critical updates on partnering and global developments
• How are policy makers shaping the contours of this new generic frontier, and what implications they have for current biologic drug development and patent protection?
• What is the authorised Biosimilarand how will this affect your market share?
• Next generation monoclonal antibody development and clinical challenges with biosimilar drug development
• Research-based industry biosimilar strategies
• Technical case studies for analytical and clinical comparability strategies
• Gain in-depth knowledge on role of technology transfer - How does this effect market access?
• Commercial challenges and opportunities - strategies to develop Biosimilars
• Leading Biosimilars companies share their views and strategies on successful market penetration and learn to implement best practices through recent successful strategies and business models – real time case studies
• Considerations for the analytical similarity assessments when designing a biosimilar development program
• Determining the right investments & potential returns from Biosimilars
• Considering the growing importance of biobetters over biosimilars
• Ascertaining the volume and level of safety data that will be required to prove patient safety and efficacy to facilitate approval
• Understanding the current regulatory approval standards for Biosimilars in Europe, US and ROI including for monoclonal antibodies
• Be part of a major networking opportunity

Early Discount (till 23rd December 2013):- Conference Delegate Pass (£ 700 + VAT per delegate)

We also have 3 for price of 2 available on group bookings. You can have 3 delegates attending at the price of 2.

Standard Registration (from 24th December 2013):- Conference Delegate Pass (£ 1000 + VAT per delegate)
Conference Sponsor & Exhibition Stall –Should you wish to Sponsor, or purchase a Exhibiton Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to –
Contact: - Nisha: - +44 2079983304. Email – nisha@virtueinsight.com

From: February 26, 2014 08:00
To: February 27, 2014 18:00

Thistle™ Marble Arch hotel, Bryanston Street, London, GB


Pharmaceuticals/Drug Discovery, Medical & Health Care

Contact email

Contact phone
+44 208 6361668

External link

Organized by: